vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and INDEPENDENT BANK CORP (INDB). Click either name above to swap in a different company.
INDEPENDENT BANK CORP is the larger business by last-quarter revenue ($212.5M vs $196.0M, roughly 1.1× Axsome Therapeutics, Inc.). INDEPENDENT BANK CORP runs the higher net margin — 35.5% vs -14.6%, a 50.0% gap on every dollar of revenue. On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs 46.9%). INDEPENDENT BANK CORP produced more free cash flow last quarter ($75.5M vs $-18.7M). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 24.3%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Independent Bank is a bank headquartered in Grand Rapids, Michigan. The bank has 62 branches, all of which are in Michigan.
AXSM vs INDB — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $196.0M | $212.5M |
| Net Profit | $-28.6M | $75.3M |
| Gross Margin | — | — |
| Operating Margin | -13.8% | — |
| Net Margin | -14.6% | 35.5% |
| Revenue YoY | 65.0% | 46.9% |
| Net Profit YoY | 61.9% | 50.6% |
| EPS (diluted) | $-0.55 | $1.51 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $196.0M | $212.5M | ||
| Q3 25 | $171.0M | $203.3M | ||
| Q2 25 | $150.0M | $147.5M | ||
| Q1 25 | $121.5M | $145.5M | ||
| Q4 24 | $118.8M | $144.7M | ||
| Q3 24 | $104.8M | $141.7M | ||
| Q2 24 | $87.2M | $137.9M | ||
| Q1 24 | $75.0M | $137.4M |
| Q4 25 | $-28.6M | $75.3M | ||
| Q3 25 | $-47.2M | $34.3M | ||
| Q2 25 | $-48.0M | $51.1M | ||
| Q1 25 | $-59.4M | $44.4M | ||
| Q4 24 | $-74.9M | $50.0M | ||
| Q3 24 | $-64.6M | $42.9M | ||
| Q2 24 | $-79.3M | $51.3M | ||
| Q1 24 | $-68.4M | $47.8M |
| Q4 25 | -13.8% | — | ||
| Q3 25 | -27.0% | 21.8% | ||
| Q2 25 | -24.5% | 44.6% | ||
| Q1 25 | -46.9% | 39.3% | ||
| Q4 24 | -61.1% | — | ||
| Q3 24 | -59.8% | 39.0% | ||
| Q2 24 | -89.5% | 48.1% | ||
| Q1 24 | -89.7% | 45.5% |
| Q4 25 | -14.6% | 35.5% | ||
| Q3 25 | -27.6% | 16.8% | ||
| Q2 25 | -32.0% | 34.6% | ||
| Q1 25 | -48.9% | 30.5% | ||
| Q4 24 | -63.1% | 34.6% | ||
| Q3 24 | -61.7% | 30.3% | ||
| Q2 24 | -91.0% | 37.2% | ||
| Q1 24 | -91.1% | 34.8% |
| Q4 25 | $-0.55 | $1.51 | ||
| Q3 25 | $-0.94 | $0.69 | ||
| Q2 25 | $-0.97 | $1.20 | ||
| Q1 25 | $-1.22 | $1.04 | ||
| Q4 24 | $-1.54 | $1.18 | ||
| Q3 24 | $-1.34 | $1.01 | ||
| Q2 24 | $-1.67 | $1.21 | ||
| Q1 24 | $-1.44 | $1.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $322.9M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $88.3M | $3.6B |
| Total Assets | $689.8M | $24.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $322.9M | — | ||
| Q3 25 | $325.3M | — | ||
| Q2 25 | $303.0M | — | ||
| Q1 25 | $300.9M | — | ||
| Q4 24 | $315.4M | — | ||
| Q3 24 | $327.3M | — | ||
| Q2 24 | $315.7M | — | ||
| Q1 24 | $331.4M | — |
| Q4 25 | $88.3M | $3.6B | ||
| Q3 25 | $73.7M | $3.5B | ||
| Q2 25 | $73.1M | $3.1B | ||
| Q1 25 | $53.2M | $3.0B | ||
| Q4 24 | $57.0M | $3.0B | ||
| Q3 24 | $92.9M | $3.0B | ||
| Q2 24 | $102.9M | $2.9B | ||
| Q1 24 | $144.0M | $2.9B |
| Q4 25 | $689.8M | $24.9B | ||
| Q3 25 | $669.3M | $25.0B | ||
| Q2 25 | $639.8M | $20.0B | ||
| Q1 25 | $596.7M | $19.9B | ||
| Q4 24 | $568.5M | $19.4B | ||
| Q3 24 | $561.5M | $19.4B | ||
| Q2 24 | $548.2M | $19.4B | ||
| Q1 24 | $545.7M | $19.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.7M | $78.9M |
| Free Cash FlowOCF − Capex | $-18.7M | $75.5M |
| FCF MarginFCF / Revenue | -9.6% | 35.5% |
| Capex IntensityCapex / Revenue | 0.0% | 1.6% |
| Cash ConversionOCF / Net Profit | — | 1.05× |
| TTM Free Cash FlowTrailing 4 quarters | $-93.9M | $239.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-18.7M | $78.9M | ||
| Q3 25 | $1.0M | $52.2M | ||
| Q2 25 | $-32.4M | $106.7M | ||
| Q1 25 | $-43.4M | $13.3M | ||
| Q4 24 | $-26.2M | $42.9M | ||
| Q3 24 | $-18.6M | $70.2M | ||
| Q2 24 | $-30.1M | $65.6M | ||
| Q1 24 | $-53.5M | $51.1M |
| Q4 25 | $-18.7M | $75.5M | ||
| Q3 25 | $988.0K | $49.7M | ||
| Q2 25 | $-32.4M | $102.5M | ||
| Q1 25 | $-43.7M | $11.3M | ||
| Q4 24 | $-26.2M | $36.5M | ||
| Q3 24 | $-18.7M | $64.4M | ||
| Q2 24 | $-30.2M | $61.9M | ||
| Q1 24 | $-53.6M | $46.7M |
| Q4 25 | -9.6% | 35.5% | ||
| Q3 25 | 0.6% | 24.4% | ||
| Q2 25 | -21.6% | 69.5% | ||
| Q1 25 | -36.0% | 7.8% | ||
| Q4 24 | -22.1% | 25.2% | ||
| Q3 24 | -17.9% | 45.4% | ||
| Q2 24 | -34.6% | 44.9% | ||
| Q1 24 | -71.4% | 34.0% |
| Q4 25 | 0.0% | 1.6% | ||
| Q3 25 | 0.0% | 1.2% | ||
| Q2 25 | 0.0% | 2.9% | ||
| Q1 25 | 0.3% | 1.4% | ||
| Q4 24 | 0.0% | 4.4% | ||
| Q3 24 | 0.1% | 4.1% | ||
| Q2 24 | 0.1% | 2.7% | ||
| Q1 24 | 0.1% | 3.2% |
| Q4 25 | — | 1.05× | ||
| Q3 25 | — | 1.52× | ||
| Q2 25 | — | 2.09× | ||
| Q1 25 | — | 0.30× | ||
| Q4 24 | — | 0.86× | ||
| Q3 24 | — | 1.64× | ||
| Q2 24 | — | 1.28× | ||
| Q1 24 | — | 1.07× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
